Alvotech completes acquisition of xbrane r&d organization and biosimilar candidate to cimzia®

Alvotech (nasdaq: alvo, alvo-sdb), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with xbrane biopharma ab (“xbrane”), with the acqusition of the r&d organization of xbrane in sweden and biosimilar candidate to cimzia® (certolizumab pegol). all regulatory conditions have been fulfilled.
ALVO Ratings Summary
ALVO Quant Ranking